Samil Pharm Cash Flow-to-Debt Ratio
Samil Pharm cash flow-to-debt ratio. Samil Pharm (000520) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2025, meaning its operating cash flow of ₩2.44 Billion could theoretically repay 0% of its total liabilities (₩226.31 Billion) in one year. Check how aggressively does Samil Pharm reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Samil Pharm (2012–2024)
Cash flow-to-debt ratio of Samil Pharm from 2012 to 2024. Historical debt coverage capacity for Samil Pharm across 13 annual periods. Check 000520 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Samil Pharm Cash Flow-to-Debt Ratio by Year (2012–2024)
Samil Pharm cash flow-to-debt ratio by year from 2012 to 2024. Year-by-year debt coverage analysis for Samil Pharm. For the full cash flow conversion analysis, see 000520 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.01x | ₩2.59 Billion | ₩218.95 Billion | ▼ -75.5% |
| 2023 | 0.05x | ₩11.75 Billion | ₩242.85 Billion | ▲ +168.8% |
| 2022 | 0.02x | ₩4.15 Billion | ₩230.88 Billion | ▲ +104.0% |
| 2021 | 0.01x | ₩1.42 Billion | ₩160.66 Billion | ▼ -85.5% |
| 2020 | 0.06x | ₩7.77 Billion | ₩128.11 Billion | ▼ -30.3% |
| 2019 | 0.09x | ₩10.59 Billion | ₩121.60 Billion | ▲ +405.2% |
| 2018 | -0.03x | ₩-2.62 Billion | ₩91.87 Billion | ▼ -163.5% |
| 2017 | 0.04x | ₩3.79 Billion | ₩84.31 Billion | ▼ -61.6% |
| 2016 | 0.12x | ₩5.63 Billion | ₩48.12 Billion | ▲ +80.0% |
| 2015 | 0.07x | ₩2.92 Billion | ₩44.90 Billion | ▲ +128.8% |
| 2014 | -0.23x | ₩-11.92 Billion | ₩52.88 Billion | ▼ -158.2% |
| 2013 | -0.09x | ₩-3.99 Billion | ₩45.68 Billion | ▼ -183.7% |
| 2012 | 0.10x | ₩5.02 Billion | ₩48.12 Billion | — |